Striking a Balance

1. Kento Fujiwara, Mizuki Masutani, Masashi Tachibana, Naoki Okada, Impact of scFv structure in chimeric antigen receptor on receptor expression efficiency and antigen recognition properties, Biochemical and Biophysical Research Communications, Volume 527, Issue 2,2020, Pages 350-357, ISSN 0006-291X,

https://doi.org/10.1016/j.bbrc.2020.03.071.

2. Yee, C., Thompson, J. A., Byrd, D. R., Riddell, S. R., Roche, P. C., Celis, E., … & Greenberg, P. D. (2002). Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred t cells. Proceedings of the National Academy of Sciences, 99(25), 16168-16173. https://doi.org/10.1073/pnas.242600099.

3. Gideon Gross, Tova Waks, and Zelig Eshhar. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc. Natl. Acad. Sci. USA. Vol. 86, pp. 10024-10028, December 1989. Immunology.

4. Krause A, Guo HF, Latouche JB, Tan C, Cheung NK, Sadelain M. Antigen-dependent CD28 signaling selectively enhances survival and proliferation in genetically modified activated human primary T lymphocytes. J Exp Med. 1998 Aug 17;188(4):619-26. doi: 10.1084/jem.188.4.619. PMID: 9705944; PMCID: PMC2213361.

5. Maher, J., Brentjens, R., Gunset, G. et al. Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRζ /CD28 receptor. Nature Biotechnology 20, 70–75 (2002). https://doi.org/10.1038/nbt0102-70

6. Brentjens, R., Latouche, JB., Santos, E. et al. Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15. Nat Med 9, 279–286 (2003). https://doi.org/10.1038/nm827

7. Renier J. Brentjens et al., CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia. Sci. Transl. Med. 5,177ra38-177ra38(2013). DOI:10.1126/scitranslmed.3005930

8. Eyquem, J., Mansilla-Soto, J., Giavridis, T. et al. Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection. Nature 543, 113–117 (2017). https://doi.org/10.1038/nature21405

9. Tran E, Turcotte S, Gros A, Robbins PF, Lu YC, Dudley ME, Wunderlich JR, Somerville RP, Hogan K, Hinrichs CS, Parkhurst MR, Yang JC, Rosenberg SA. Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science. 2014 May 9;344(6184):641-5. doi: 10.1126/science.1251102. PMID: 24812403; PMCID: PMC6686185.

10. Kim JH, Hong HJ. Humanization by CDR grafting and specificity-determining residue grafting. Methods Mol Biol. 2012;907:237-45. doi: 10.1007/978-1-61779-974-7_13. PMID: 22907355.

11. Davey AS, Call ME, Call MJ. The Influence of Chimeric Antigen Receptor Structural Domains on Clinical Outcomes and Associated Toxicities. Cancers. 2021; 13(1):38. https://doi.org/10.3390/cancers13010038